



Lung Cancer & COVID 19: Lessons, Experiences, Strategies

Guest Editors:

Dr. Giulia M. Stella

Dr. Torsten Gerriet Blum

Prof. Dr. Andrea Bianco

Deadline for manuscript
submissions:
closed (31 May 2023)

Message from the Guest Editors

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to several causes, including their immunocompromised state due to antineoplastic therapies, use of steroids, comorbidities and frequently advanced age, and frequent hospital visits. The clinical pictures of the infection can vary from mild flu-like conditions to severe pneumonia, which can evolve to acute respiratory alveolar damage (ARDS) and multiorgan failure. Moreover, the cytokine storm is implicated in the generation of aberrant immunological responses against the virus, which ultimately produce lung parenchymal acute and severe damage responsible for evolution to chronic fibrosis and, in worse cases, patient death. The goal of the present issue is to summarize, according to a multidisciplinary perspective, the lessons and experiences derived from the pandemic waves and to design strategies for future co-existence with SARS-CoV-2 to ensure safer and better outcomes for cancer patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
 [@Cancers_MDPI](https://twitter.com/Cancers_MDPI)